Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (105)	8/15/1998 9:12:00 AM
From: PDavid	Read Replies (1) \| Respond to of 666

Rick Harmon-just a quick response to your check on the TCLN CEO While the background check that you did produced a question as to whether Bymaster played a role in hurting xytronix, I can state that he did not. The events that caused the downward spiral preceded his tenure as CEO, though he was with the company. As CEO, he transformed the company into a cancer therapeutics company (from whatever they were doing in the dental field), which eventually led to the name change. In reality, he saved the company, ushered in new financing and developed increased credibility with the public (which was desperately needed after the debacle). He also developed a fine relationship with the FDA. I apologize in advance for this post, as I am a tcln shareholder and have no intentions on offending anybody over here. I just saw your post and wanted to clarify some things. I met Bymaster in a recent shareholders luncheon in New York. He was questioned about his association with Xytronix and addressed the very concern that you raised. Phil

To: scaram(o)uche who wrote (105)	8/15/1998 4:43:00 PM
From: shero	Read Replies (1) \| Respond to of 666

TNT data from the glioma trial should be out by years end. If I didn't already own TCLN I'd wait for the facts. As for bad financing deals the past is the past. There is about 17MM left in an equity line available, this was previously announced. No need to take down the money until it is needed, if the stock goes up alittle the terms are better. If LYM-1 is licensed soon that will bring in some non-dilutive funding. If this deal isn't complete by Aug.31 (if memeory serve me correctly) Legere gets the rights, so something may happen soon. Sorry to trespass, responsible comments and critisism will always be appreciated. Feel free to post on TCLN thread.